title: T cell depleted stem-cell transplantation for adults with hematologic malignancies: sustained engraftment of HLA-matched related donor grafts without the use of antithymocyte globulin.
abstract: Antithymocyte globulin (ATG) has been used in allogeneic stem-cell transplantation to prevent graft rejection and graft-versus-host disease (GvHD). Its use, however, has been associated with delayed T-cell reconstitution and prolonged susceptibility to opportunistic infections (OIs) especially in patients undergoing T cell-depleted (TCD) transplantation. Recently, a prospective trial was conducted in 52 adult patients (median age, 47 years) with various hematologic malignancies undergoing TCD transplantation from HLA-matched related donors without the use of ATG. The cytoreductive regimen consisted of hyperfractionated total body irradiation (HFTBI), thiotepa, and fludarabine. The preferred source of the graft was peripheral blood stem cells (PBSCs). No additional graft rejection or GvHD prophylaxis was given. All evaluable patients engrafted without any immune-mediated graft rejections. Disease-free survival (DFS) at 3 years was 61% in all patients, and 70% in patients with standard-risk disease. Acute GvHD was limited to grade 2 in 8% and chronic GvHD in 9% of patients. Life-threatening OIs occurred in 3 of 52 patients and was fatal in 1. This study demonstrates durable engraftment with a low incidence of GvHD despite the lack of ATG, as well as the curative potential of this regimen.
authors: Adult Allogeneic Bone Marrow Transplant Service, Division of Hematologic-Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, Weill Medical College of Cornell University, New York, NY 10065, USA. jakubowa@mskcc.org
authors: Ann A
authors: AA
authors: Jakubowski
authors: Trudy N
authors: TN
authors: Small
authors: James W
authors: JW
authors: Young
authors: Nancy A
authors: NA
authors: Kernan
authors: Hugo
authors: H
authors: Castro-Malaspina
authors: Katherine C
authors: KC
authors: Hsu
authors: Miguel-Angel
authors: MA
authors: Perales
authors: Nancy
authors: N
authors: Collins
authors: Christine
authors: C
authors: Cisek
authors: Michelle
authors: M
authors: Chiu
authors: Marcel R M
authors: MR
authors: van den Brink
authors: Richard J
authors: RJ
authors: O'Reilly
authors: Esperanza B
authors: EB
authors: Papadopoulos
mesh_terms: D000328:Adult; D000961:Antilymphocyte Serum; D018572:Disease-Free Survival; D005260:Female; D006085:Graft Survival; D006086:Graft vs Host Disease; D006680:HLA Antigens; D019337:Hematologic Neoplasms / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D008212:Lymphocyte Depletion; D008297:Male; D008875:Middle Aged; D009894:Opportunistic Infections; D019172:Transplantation Conditioning / Q000379:methods; D014184:Transplantation, Homologous
chemical_list: D000961:Antilymphocyte Serum; D006680:HLA Antigens
references: J Clin Microbiol. 2000 Feb;38(2):712-5
references: 10655372
references: Clin Infect Dis. 2004 Dec 1;39(11):1625-32
references: 15578362
references: Blood. 2001 Dec 1;98(12):3221-7
references: 11719357
references: Blood. 2002 Aug 1;100(3):761-7
references: 12130483
references: Blood. 2002 Dec 15;100(13):4325-36
references: 12393746
references: Blood. 2003 Jan 15;101(2):446-53
references: 12393406
references: Bone Marrow Transplant. 2003 Jun;31(12):1089-95
references: 12796788
references: Blood. 2003 Nov 15;102(10):3521-9
references: 12893748
references: Blood. 2004 Sep 15;104(6):1616-23
references: 15059843
references: Transplantation. 1974 Oct;18(4):295-304
references: 4153799
references: Am J Med. 1980 Aug;69(2):204-17
references: 6996481
references: Int J Radiat Oncol Biol Phys. 1983 Nov;9(11):1607-11
references: 6358154
references: Blood. 1986 Sep;68(3):770-3
references: 3527302
references: Blood. 1989 Nov 1;74(6):2227-36
references: 2804361
references: Blood. 1989 Nov 1;74(6):2237-43
references: 2529927
references: Blood. 1992 Jun 15;79(12):3380-7
references: 1596577
references: Immunol Today. 1995 Sep;16(9):437-40
references: 7546208
references: Immunol Rev. 1997 Jun;157:195-216
references: 9255631
references: Biol Blood Marrow Transplant. 1997 Jun;3(2):65-75
references: 9267666
references: Blood. 1998 Feb 1;91(3):1083-90
references: 9446672
references: J Clin Oncol. 2005 Mar 20;23(9):1993-2003
references: 15774790
references: Am J Hematol. 2005 Apr;78(4):265-74
references: 15795914
references: Leukemia. 2005 May;19(5):822-8
references: 15772701
references: J Clin Oncol. 2005 May 20;23(15):3439-46
references: 15824415
references: Biol Blood Marrow Transplant. 2005 Jun;11(6):437-47
references: 15931632
references: J Clin Oncol. 2005 Aug 1;23(22):5074-87
references: 16051954
references: Biol Blood Marrow Transplant. 2006 Apr;12(4):438-53
references: 16545728
references: Clin Transplant. 2006 Jan-Feb;20(1):127-31
references: 16556167
references: Transplantation. 2006 Mar 27;81(6):818-25
references: 16570002
references: Biol Blood Marrow Transplant. 2006 May;12(5):573-84
references: 16635793
references: Biol Blood Marrow Transplant. 2006 Jul;12(7):703-11
references: 16785059
references: J Clin Oncol. 2006 Dec 20;24(36):5695-702
references: 17116940
references: Blood. 1999 Jan 15;93(2):467-80
references: 9885208
references: Blood. 1999 Aug 15;94(4):1465-70
references: 10438735
references: Blood. 2004 Nov 15;104(10):3028-37
references: 15256423
references: Blood. 2001 Feb 1;97(3):631-7
references: 11157478